Blocking one protein slowed a rare childhood brain tumor in lab and mouse tests
Original title: Nuclear export inhibition activates TP53 pathways and is a potent therapeutic strategy in atypical teratoid rhabdoid tumors.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done in tumor cells and in mice, not in people.
The short version
In lab dishes and in mice, blocking a protein called XPO1 slowed a rare brain tumor that mostly hits young children.
What was studied. Researchers looked at ATRT, a fast growing brain tumor found mostly in young children. They tested what happens when a protein called XPO1 is shut off or blocked, using tumor cells from patients and mice with the tumor in the brain.
What they found. ATRT cells made a lot of XPO1. That was more than other children's brain tumor cells made. Shutting off XPO1 slowed the tumor cells. Blocking it with 6 different drugs did the same. In mice, one of those drugs, selinexor, was given with radiation and a chemo drug. The tumors got smaller and the mice lived longer.
What this means, and what it doesn't
What it could mean: XPO1 may be a useful target for new ATRT treatments. Today's treatments are very hard on young children, so gentler options are badly needed. This gives researchers a reason to keep testing this idea.
What it doesn't mean: This does not mean a new treatment is ready. The work was done in tumor cells and in mice, not in children. It does not show that the drug helps a child with ATRT. It is not a cure, and it is not something a doctor can give you today. Tests in people would have to come first.
Source: PubMed, August 10, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.